Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2291]

Latest in hormone sensitive prostate cancer

Prof Eleni Efstathiou, Prof Boris Hadaschik, Prof Gerhardt Attard and Prof...

Latest in hormone sensitive prostate cancer ( Prof Eleni Efstathiou, Prof Boris Hadaschik, Prof Gerhardt Attard and Prof Heather Payne )

3 year follow-up of the CheckMate 9ER trial: NIVO + cabozantinib vs sunitinib...

Dr Mauricio Burotto - Bradford Hill, Recoleta, Chile

3 year follow-up of the CheckMate 9ER trial: NIVO + cabozantinib vs sunitinib for first-line treatment of aRCC ( Dr Mauricio Burotto - Bradford Hill, Recoleta, Chile )

Plasma miR371 detects MRD and early relapse of germ cell tumours

Dr Lucia Nappi - University of British Columbia, Vancouver, Canada

Plasma miR371 detects MRD and early relapse of germ cell tumours ( Dr Lucia Nappi - University of British Columbia, Vancouver, Canada )

Adaptive image-guided radiotherapy in muscle-invasive bladder cancer shows low...

Prof Robert A Huddart - Royal Marsden NHS Foundation Trust, London, UK

Adaptive image-guided radiotherapy in muscle-invasive bladder cancer shows low toxicity and good outcomes ( Prof Robert A Huddart - Royal Marsden NHS Foundation Trust, London, UK )

Cabozantinib after checkpoint inhibitors demonstrates preliminary efficacy in...

Dr Laurence Albiges - Institut Gustave Roussy, Villejuif, France

Cabozantinib after checkpoint inhibitors demonstrates preliminary efficacy in advanced RCC ( Dr Laurence Albiges - Institut Gustave Roussy, Villejuif, France )

Final OS results of IMvigor130: Atezolizumab plus platinum/gemcitabine for mUC

Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA

Final OS results of IMvigor130: Atezolizumab plus platinum/gemcitabine for mUC ( Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA )

Gemcitabine, cisplatin plus nivolumab achieves clinical complete response in...

Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA

Gemcitabine, cisplatin plus nivolumab achieves clinical complete response in subset of muscle-invasive bladder cancer patients ( Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA )

Adjuvant nivolumab as standard of care for high-risk muscle-invasive urothelial...

Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA

Adjuvant nivolumab as standard of care for high-risk muscle-invasive urothelial carcinoma after radical resection ( Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA )

ASCO GU 2023: Latest real world data in prostate cancer

Prof Phil Cornford and Prof Laura-Maria Krabbe

ASCO GU 2023: Latest real world data in prostate cancer ( Prof Phil Cornford and Prof Laura-Maria Krabbe )

Hypofractionated high dose intensity modulated radiotherapy non-inferior for...

Prof Joe M O'Sullivan - Queen's University Belfast, Belfast, UK

$Hypofractionated high dose intensity modulated radiotherapy non-inferior for prostate cancer ( Prof Joe M O'Sullivan - Queen's University Belfast, Belfast, UK )$

JAVELIN Bladder 100: Avelumab maintenance indicated as a standard of care for...

Dr Srikala Sridhar - Princess Margaret Cancer Centre, Ontario, Canada

JAVELIN Bladder 100: Avelumab maintenance indicated as a standard of care for advanced urothelial carcinoma ( Dr Srikala Sridhar - Princess Margaret Cancer Centre, Ontario, Canada )

HER2DX: a new diagnostic tool for early-stage HER2 positive breast cancer

Prof Aleix Prat - Hospital Clínic Barcelona, Barcelona, Spain

HER2DX: a new diagnostic tool for early-stage HER2 positive breast cancer ( Prof Aleix Prat - Hospital Clínic Barcelona, Barcelona, Spain )

More from ecancer